Zenas BioPharma sets price range for $200 million initial public offering

Zenas BioPharma Inc., a Waltham, Mass.-based developer of immunology-based therapies, on Friday said it plans to offer 11.76 million shares of common stock at an estimated price range of $16 to $18 in its upcoming initial public offering.

Previous post Russian court blocks Austria’s Raiffeisen Bank from selling local subsidiary
Next post August payrolls grew by a less-than-expected 142,000, but unemployment rate ticked down to 4.2%